Skip to content

MAKING BEST PRACTICE, EVERYDAY PRACTICE

FREE accredited digital CPD for health care professionals in South Africa

Accredited by the University of Pretoria

MAKING BEST PRACTICE, EVERYDAY PRACTICE

FREE accredited digital CPD for health care professionals in South Africa

Accredited by the University of Pretoria

Menu

Home
About
- About Us
- FAQs
- Sponsors
All clinical topics
SPECIAL INTEREST GROUPS
- Medical interns and registrars
Contact
ACCESS MY PROFILE

Menu

Home
About
- About Us
- FAQs
- Sponsors
All clinical topics
SPECIAL INTEREST GROUPS
- Medical interns and registrars
Contact
ACCESS MY PROFILE

[denovo_breadcrumbs]

In-time insulin intervention – The right insulin, the right patient (Case study summary 1)

Questionnaire

To access this module, please register or login:

Login or Register

In-time insulin intervention – The right insulin, the right patient
In-time insulin intervention – The right insulin, the right patient (Case study summary 1)

Time limit: 0

Questionnaire Summary

0 of 10 Questions completed

Questions:

Information

You have already completed the questionnaire before. Hence you can not start it again.

Questionnaire is loading…

You must sign in or sign up to start the questionnaire.

You must first complete the following:

Results

Questionnaire complete. Results are being recorded.

Results

0 of 10 Questions answered correctly

Time has elapsed

You have reached 0 of 0 point(s), (0)

Earned Point(s): 0 of 0, (0)
0 Essay(s) Pending (Possible Point(s): 0)

Categories

Not categorized 0%

Regrettably, you have failed to achieve the 70% pass mark required by the accrediting HPCSA.

Please read/watch the module carefully and try once more! (Only two tries are allowed)

PLEASE NOTE: you will no longer receive a fail confirmation email.
Congratulations on successfully completing this FREE CPD module!

For HPCSA members only: No need to load your certificate on HPCSA, as deNovo Medica uploads these weekly. Please allow 5-10 working days for the CPD activity to reflect on your HPCSA profile.

For non-HPCSA members: The above button allows you to download and print your CPD certificate to submit to your council yourself.

PLEASE NOTE: you will no longer receive a pass confirmation email! Visit YOUR PROFILE to find all your CPD certificates and activities completed.

Review
Answered
Correct
Incorrect

Question 1 of 10

1. Question

1. In case study 1, Mrs KM had an HbA1c of 10.4% despite triple antidiabetic therapy. What was the underlying cause of her poor glycaemic control?

A. Non-adherence to medication
Correct Incorrect Correct answer

B. Drug-drug interactions
Correct Incorrect Correct answer

C. Progression of her diabetes
Correct Incorrect Correct answer

D. Incorrect treatment
Correct Incorrect Correct answer
Question 2 of 10

2. Question

2. What is the main reason for initiating basal insulin in patients with T2DM who fail oral therapy?

A. To address other risk factors associated with diabetes
Correct Incorrect Correct answer

B. To improve hyperglycaemia control to achieve the target HbA1c
Correct Incorrect Correct answer

C. To replace oral antidiabetic medications
Correct Incorrect Correct answer

D. To improve cardiovascular outcomes
Correct Incorrect Correct answer
Question 3 of 10

3. Question

3. Why was it important to use a second-generation basal insulin, such as insulin glargine U300, for Mrs KM?

A. It improves the ability to reach the target HbA1c level
Correct Incorrect Correct answer

B. Insulin glargine 300 units/ml is a longer-acting insulin with a more stable pharmacokinetic profile
Correct Incorrect Correct answer

C. It reduces the risk of hypoglycaemic episodes
Correct Incorrect Correct answer

D. To reduce the need for ongoing glucose monitoring
Correct Incorrect Correct answer

E. A, B and C
Correct Incorrect Correct answer
Question 4 of 10

4. Question

4. Which oral antidiabetic medication should be discontinued to reduce the risk of hypoglycaemia?

A. Metformin
Correct Incorrect Correct answer

B. Semaglutide
Correct Incorrect Correct answer

C. Simvastatin
Correct Incorrect Correct answer

D. Gliclazide MR
Correct Incorrect Correct answer
Question 5 of 10

5. Question

5. In GDM which FPG level is recommended?

A. <7.0 mmol/L
Correct Incorrect Correct answer

B. <6.0 mmol/L
Correct Incorrect Correct answer

C. <5.3 mmol/L
Correct Incorrect Correct answer

D. <4.5 mmol/L
Correct Incorrect Correct answer
Question 6 of 10

6. Question

6. This patient with GDM had controlled PPG levels but persistent fasting hyperglycaemia. Which treatment should be started?

A. Add rapid-acting insulin before meals
Correct Incorrect Correct answer

B. Start basal insulin therapy
Correct Incorrect Correct answer

C. Start metformin
Correct Incorrect Correct answer

D. Start glyburide or glibenclamide
Correct Incorrect Correct answer
Question 7 of 10

7. Question

7. Why does insulin remain the gold-standard pharmacological treatment for GDM?

A. It improves weight loss during pregnancy
Correct Incorrect Correct answer

B. It does not cross the placenta and allows precise glucose control
Correct Incorrect Correct answer

C. It prevents post-partum T2DM
Correct Incorrect Correct answer

D. It requires less monitoring than other therapies
Correct Incorrect Correct answer
Question 8 of 10

8. Question

8. In older adults with T2DM, what is a major advantage of insulin glargine U300 compared with insulin glargine U100?

A. Greater weight reduction
Correct Incorrect Correct answer

B. Lower rates of symptomatic hypoglycaemia
Correct Incorrect Correct answer

C. Improved renal function
Correct Incorrect Correct answer

D. Improved cardiovascular outcomes
Correct Incorrect Correct answer
Question 9 of 10

9. Question

9. According to the SENIOR study, insulin glargine U300 demonstrated which of the following benefits in patients aged 75 years and older?

A. Increased insulin sensitivity
Correct Incorrect Correct answer

B. A 55% reduction in symptomatic hypoglycaemia rates compared with insulin glargine U100
Correct Incorrect Correct answer

C. Prevention of diabetic complications
Correct Incorrect Correct answer

D. No need for titration of insulin
Correct Incorrect Correct answer
Question 10 of 10

10. Question

10. Which characteristics of insulin glargine U300 most strongly support its use across all three case studies? Its ability to:

A. Achieve rapid blood glucose control
Correct Incorrect Correct answer

B. Achieve optimal glycaemic control and minimise the risk of hypoglycaemia
Correct Incorrect Correct answer

C. Manage other co-morbidities
Correct Incorrect Correct answer

D. Reduce negative cardiovascular and renal outcomes
Correct Incorrect Correct answer

All Rights Reserved 2026 © deNovo Medica (Pty) Ltd in South Africa. The content on this website is intended for healthcare related professionals unless stated otherwise.

Get involved

Become a sponsor Become a medical partner author/reviewer/society

Get involved

Become a sponsor Become a medical partner author/reviewer/society

Login

Accessing this module requires a login. Please enter your credentials below!

Username or Email Address

Password

Remember Me

Lost Your Password?